Pharma

Your Article Summary

See Latest Articles

Tengion Announces Second Closing of Series C Financing
Corporate News Releases - The Healthcare Sales & Marketing Network, 11/20/08

Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-tissues, announced that it has completed a second closing of its Series C financing, receiving a total of approximately $21 million in additional equity capital from the company's existing institutional equity investor base along with new investor, Safeguard Scientifics, Inc. Tengion also announced that Gary J. Kurtzman, M.D., Vice President and Managing Director of Safeguard Scientifics' Life Sciences Group, has joined Tengion's Board of Directors.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Greater chances of cure for patients with HER2-positive early breast cancer when treated with one year of Herceptin
Roche, 12/14/09

Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancer
Roche, 12/14/09

ImmunoGen, Inc. Announces Positive Trastuzumab-DM1 Clinical Data Reported at the San Antonio Breast Cancer Symposium
ImmunoGen, Inc., 12/14/09

 See all of Research & Development